# Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-11 04:29 UTC · Category: Business · Sources: 9 · Current Velocity: 7.5

## Executive Summary
Sanofi's Sarclisa becomes the first cancer drug approved by the FDA for delivery via an on-body injector for multiple myeloma.

## Intelligence Brief
The US FDA has approved Sarclisa Escena (isatuximab-irfc), a subcutaneous formulation used to treat multiple myeloma. This marks the first time a cancer drug has been approved for delivery via a wearable, on-body injector.


Coverage from Reuters, Fierce Pharma, and Pharmaceutical Executive emphasizes the novelty of the delivery method. The Journal of Managed Care notes that this approval increases competition among anti-CD38 therapies.


Yahoo Finance further reports that this regulatory win coincides with the European Union opening an antitrust probe into Sanofi. Industry focus remains on the clinical implications of isatuximab-irfc's approval and the subsequent impact on the multiple myeloma treatment landscape.

## Verified Facts & Key Claims
### What is Sarclisa Escena used for?
It is used for the treatment of multiple myeloma.

### What makes this FDA approval unique?
It is the first cancer drug approved for delivery through an on-body injector.

### Which company developed the drug?
The drug was developed by Sanofi.

## Key People, Organizations & Locations
FDA, US FDA, Sanofi, Sarclisa, FDA Approves Subcutaneous Sarclisa Escena, Implications, FDA Approval for Multiple Myeloma, Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma, Wins FDA Nod For Sarclisa Escena As EU Opens Antitrust Probe, FDA Approves Isatuximab-Irfc For Subcutaneous Injection For Multiple Myeloma Indications On July

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Oncodaily | Galina Bernstein: FDA Approves Subcutaneous Isatuximab for Multiple Myeloma | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMiY0FVX3lxTFA4SnNrRmNPbHJuSjVTdU44S2t0aDQyNmxzak9rTFlLaHVSQnEzTEt0a0prZVZ3N3FYZGs5SHZHamVUOTF4TVdwLXRqRjVZX3RIc3BkMUdKcmR2MEFPMTRUU2dyRQ?oc=5) |
| Oncodaily | FDA Approves Subcutaneous Isatuximab for Multiple Myeloma | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMifkFVX3lxTFBFYWRWQkpWMnA4ZlBDcUFPeDZMcWozeUc1Tkk0amZDdkFFMVA0dzU5QklrMVlaTWN4OWZRV0xmdE1vTmNGeVZaTHdRUXBMa2RCOWNJNkxmZnZFRlY2LU1rZGZjVDVGRExxTjE3QXBSMUgxSU84dXBLdnZpdExCdw?oc=5) |
| Journal of Managed Care | FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxOR2w5V2c2QlFkOWZsOUN2eF9YU3ZuNUhtY3N1WnkwRjhKMmQxTUxYQ2R5RUFpdFVFLXVFVjJPUE1FYzRkdUpKWnRraFlMNWxKT2NuQXI2a2RBWS1HUHViVW9GcWQtbmU5N3FaLWdDMjh6c2JpZDZKa0djSDQzZzhUNC1VY1BLNk81OU44UGhDVjBiOF9VVU9GNmM4cklEb3YwUkI3MGM2Y2M1LXktYklKU0tSUzZ5Vl9WLV9nbUtUOA?oc=5) |
| Yahoo Finance | Sanofi (ENXTPA:SAN) Wins FDA Nod For Sarclisa Escena As EU Opens Antitrust Probe | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxOWkRnVkoyQzlWYU5Vb2ZfS24tWnhOaExxWTY3T1RqWVpoRU1ybzEyX3lyWTlPaElCWEdzYTlJMEJ1N1Z3bUN5Z2w0czFtZHN2VFJ2b0s5NW43aFlrbl9objZGbm1xbVVVY09ySzE4RU92ejVFcS1Ea0RNNnhZc0ExRXZnYVlUQk5CT0p0SDdhVU8?oc=5) |
| TradingView | FDA Approves Isatuximab-Irfc For Subcutaneous Injection For Multiple Myeloma Indications On July 9 | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMi_AFBVV95cUxQckg2aWE2QkxRWTQ4MXlybWxnZzlDLXRqb1hUdXdYa0RxTC1rX1RvVzlpWVhQOGJiY2c1UHZaTlRqMzQ4SjRWQ3B6eVpNU3hqSEdCQ3M2V2dUa2xXd3R3UXNpVS1UcDR5ZUZkZk1McnBzbkdqQnF3NWlzYjBDWW9TeWNieURwakpucS13M3dfYnBqTnNveFN4YmY2WUV6eG90M2hTYkdWbkUtQ2hHdXNWcTh4UnVzeWFvZmhLZnoxbGRKdnBjNy1oNEJFLUtkak1zYnF5aWVmUXpVTVBodW04NFFOZllXQmtaaE5ubEdMWVRQcjBBWmhOMEQyUks?oc=5) |
| Pharmaceutical Executive | FDA Approves Subcutaneous Sarclisa Escena | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxORE5reXViRFV4M19tbUlVanRuSWdqRGVldi1iUm8zOUNZSDdMc2FUdVVKZHpFYmNTc2dKYkZuWE9jRE1TX0RiUEZ5aU1fYngzUVF1RTdSX3BoOVMteVFhUzh0ZEpsQnUybGdJNHVySFI2RU5vLUI1YWNyMVdCYjVPQ2thRkk?oc=5) |
| PharmTech.com | The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxNYkRfLUI4akU4RkpSYk1TeHI4eFdlLTM3bGQxUjJqcjZYNFN1TC0yQUMxRTVETUx6OHZXbkYzT29KVTkyYV8yRUs4d3BGblh6NkRPeF9ISDE4VEhuaUp3YVpPVU5MNDhia1RDem1sc3ZleXJ3RG93bTF0MkxWV0xtc0ppTV9KMWhvSDZESlpabGtfZUU1YVA0dm9R?oc=5) |
| Medical Professionals Reference | Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxObUo4Y0FUMGJTWW5wdHZQWm5zbVB6QThCUVZwMWFjSGhPRThNakpDLWhfaHVLV1A2dWg1c0xjUTI3dEVsajMtNTRBZklqc2VmazhObTl4SVlNajlLa0ViT200Q0l0Um1lN3ROYllTTUtYZlRPUHAtOXdzSzg1RDljcElYWU5XZjlySGs5Rm5n?oc=5) |
| Reuters | US FDA approves Sanofi's wearable injector form of blood cancer drug | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMi0gFBVV95cUxOZnF5Sl9QS0o0Y0ZZS2dyWXRqR29fdlRMQldNV0p5TVBSc2VZaU95R0xZSVF0d1NLanRCRjdvNjFvbzkwS09sSDFQOFJ5NDIwQWd3ekZINTJMY1hBTEd2OVlZMnNSSEdFZkpfTHFUODk4Umlaazk3Q2M4bnptbHZpR2VJeTRvNV9ESmJkcUYzRE9tMWlfMVZRREs1MHUzNG1lNFU2a05sazN6RGRvS1BicG11bWVSVjhlVmo2Um5HaE1hTTB2Sk1oMG1CcUk5RVJObmc?oc=5) |
| Fierce Pharma | Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector | 2026-07-10 13:18 | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxQUE1WUmVJZ3pXazFNRmJpWjE5ZWtKYmI5UGk1MlhQOHR0c3NFM3c5TmZOTzc5RERsVkpfTGpwd0JmUnVQLTJuZzJVcGQxVC0yYjBYUmlySXNobmlRZGtCblMxRWdEQUVGYWxvU2hzQnhXUTlPak1pblFnTVJBWUM1Q2NoajBsMnJOdFBudVFjUHpOeV9TSi0tazFMM2hoVVk0RnpqM0FoT0N3SmlPeHRVVg?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-11/sanofi-snags-fda-thumbs-up-for-sarclisa-as-1st-cancer-drug-delivered-by-on-body*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*